Safety Study of Sterile Compound C31510 for Injection to Subjects with Solid Tumors

BPGbio

Status and phase: Completed; Phase 1

Conditions: Solid Tumors

Treatments: Drug: Sterile Compound C31510 for Injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT01251562

CTL0510

Details and patient eligibility

About

The primary objective of this clinical study is as follows:

• To determine the MTD and to assess the safety and tolerability of C31510 administered as a single 4-hour IV infusion (up to nine different dosages) in subjects with solid tumors

The secondary objective of this study is as follows:

• To evaluate plasma PK and estimate renal elimination of C31510 administered as a single 4-hour IV infusion (up to nine different dosages) in subjects with solid tumors

The exploratory objectives of this study are as follows:

• To evaluate the pharmacodynamic correlates of C31510 activity in plasma and peripheral blood cells
• To radiographically evaluate the effects of C31510 on tumors. In selected subjects, the effects on vascular permeability will be assessed by digital contrast enhanced (DCE)-magnetic resonance imaging (MRI)
• To evaluate tumor response (preliminary antitumor activity) after repeat administration of C31510
• Long-term safety and tolerability of C31510 after repeat administration

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The subject has a histologically confirmed solid tumor that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective.
• The subject is at least 18 years old.
• The subject has an ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.
• The subject has a life expectancy of greater than 3 months.
• The subject has organ and marrow function as follows: ANC>1500mm3, platelets>100,000 dl, hemoglobin >9 g/dL, bilirubin ≤ 1.5mg/dL, serum creatinine ≤1.5mg/dL or creatinine clearance >60 mL/min, and alanine aminotransferase (ALT), aspartate transaminase (AST) ≤2.5 times the upper limit of normal if no liver involvement or ≤5 times the upper limit of normal with liver involvement.
• The subject is capable of understanding and complying with the protocol and has signed the informed consent document.
• Sexually active subjects must use an accepted method of contraception during the course of the study.
• Female patients of childbearing potential must have a negative pregnancy test at enrollment.
• If a subject has received more than three prior regimens of cytotoxic chemotherapy, or more than two biological regimens, or more than 3000cGy to areas containing substantial marrow, the cohort review committee (CRC) must determine subject suitability prior to enrollment.

Exclusion criteria

• The subject has received chemotherapy or radiotherapy within 4 weeks or has received nitrosoureas or mitomycin C within 6 weeks prior to entering the study.
• The subject has received anti-angiogenesis drugs within 4 weeks prior to entering the study.
• The subject has received radiation to ≥25% of his or her bone marrow within 4 weeks of C31510IV treatment.
• The subject has received an investigational drug within 30 days of the first dose of study drug. 6 of 72
• The subject has not recovered to grade ≤1 from adverse events( AEs) due to investigational drugs or other medications, which were administered more than 4 weeks prior to study enrollment.
• The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• The subject is pregnant or lactating.
• The subject is known to be positive for the human immunodeficiency virus (HIV)
• The subject has an inability or unwillingness to abide by the study protocol or cooperate fully with the investigator or designee.
• Must have not taken Vitamin D3 supplements in the last 30 days
• The subject is on HMG-CoA Reductase Inhibitors
• The subject is receiving digoxin, digitoxin, lanatoside C or any type of digitalis alkaloids
• The subject is receiving Colony Stimulating factors. The use of Colony Stimulating factors isf prohibited during the monitoring of DLT in this study.
• The subject is receiving Warfarin.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 9 patient groups

Cohort 1

Experimental group

Description:

5.62 mg/kg Sterile Compound C31510 for Injection

Treatment:

Drug: Sterile Compound C31510 for Injection

Cohort 2

Experimental group

Description:

11.25 mg/kg Sterile Compound C31510 for Injection

Treatment:

Drug: Sterile Compound C31510 for Injection

Cohort 3

Experimental group

Description:

22.5 mg/kg Sterile Compound C31510 for Injection

Treatment:

Drug: Sterile Compound C31510 for Injection

Cohort 4

Experimental group

Description:

33.0 mg/kg

Treatment:

Drug: Sterile Compound C31510 for Injection

Cohort 5

Experimental group

Description:

44.0 mg/kg Sterile Compound C31510 for Injection

Treatment:

Drug: Sterile Compound C31510 for Injection

Cohort 6

Experimental group

Description:

58.7 mg/kg Sterile Compound C31510 for Injection

Treatment:

Drug: Sterile Compound C31510 for Injection

Cohort 7

Experimental group

Description:

78.2 mg/kg Sterile Compound C31510 for Injection

Treatment:

Drug: Sterile Compound C31510 for Injection

Cohort 8

Experimental group

Description:

104.3 mg/kg Sterile Compound C31510 for Injection

Treatment:

Drug: Sterile Compound C31510 for Injection

Cohort 9

Experimental group

Description:

139.0 mg/kg Sterile Compound C31510 for Injection

Treatment:

Drug: Sterile Compound C31510 for Injection